Response of Retinal Sensitivity to Intravitreal Anti-angiogenic Bevacizumab and Triamcinolone Acetonide for Patients with Diabetic Macular Edema over One Year

Autor:	Sonja Karst, Katharina Kriechbaum, Ursula Schmidt-Erfurth, Markus Schranz, Gregor Sebastian Reiter, Christoph Scholda, Lukas Baumann, Georgios Mylonas
Rok vydání:	2020
Předmět:	Male Vascular Endothelial Growth Factor A medicine.medical_specialty Triamcinolone acetonide Bevacizumab Diabetic macular edema Visual Acuity Angiogenesis Inhibitors Triamcinolone Acetonide Macular Edema Retina Cellular and Molecular Neuroscience chemistry.chemical_compound Diabetes mellitus Ophthalmology Medicine Humans In patient Prospective Studies skin and connective tissue diseases Glucocorticoids Aged Diabetic Retinopathy business.industry Anti angiogenic Retinal Middle Aged medicine.disease Sensory Systems chemistry Intravitreal Injections Visual Field Tests Female sense organs Visual Fields business Microperimetry Tomography Optical Coherence medicine.drug
Zdroj:	Current eye research. 45(9)
ISSN:	1460-2202
Popis:	The aim of this study was to evaluate and compare microperimetry changes in patients with clinically significant diabetic macular edema secondary to diabetes mellitus, following intravitreal injections of bevacizumab or triamcinolone during a follow-up of 1 year after treatment.30 patients with clinically significant macular edema were randomized into two groups of 15 patients each. One group initially received three intravitreal injections of 2.5 mg bevacizumab at monthly intervals. The other received a single injection of 8 mg of triamcinolone followed by two sham interventions at monthly intervals. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured. Macular function was documented by microperimetry at baseline, 3, 6, 9 months and at the last visit of each patient.In the bevacizumab group, the mean differential light threshold (±standard deviation) under therapy improved significantly from 8.40 (± 3.8) dB to 12.8 (±4.3) dB at the 12-month follow-up visit (p ≤ .05), whereas in the triamcinolone group it increased from 8.0 (± 2.4) dB at baseline to 9.3 (±3.6) dB at the last visit without reaching statistical significance (Central macular function as measured by microperimetry in patients with acute DME improved in addition to anatomical restoration after intravitreal bevacizumab and triamcinolone injection. In our clinical study, the measures of the variables in patients receiving bevacizumab were superior to those receiving triamcinolone throughout the one-year observation period.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b973fb655177a2fc3cfeb9910ed7b7da https://pubmed.ncbi.nlm.nih.gov/31961224 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.